🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Limoges
NCT06147843 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS. Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis. * Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany. * Patients who signed the informed consent form. * Adults aged \>18 years old Exclusion Criteria: * Inability to understand the requirements of the protocol. * Cognitive inability to sign and comprehend the informed consent form. * Patients who will not accept Riluzole therapy during their follow-up.
💊

What it tests

  • Blood sample
📍

Where

9 sites
CHU de Lille
Lille, France
Limoges University Hospital
Limoges, France
Hôpital de la Timone
Marseille, France
Hôpital Gui Chauliac
Montpellier, France
CHU de Nice
Nice, France
Hôpital de la Pitié Salpêtrière
Paris, France
CHU de Tours
Tours, France
Klinik für Medizinische Hochschule Hannover Carl-Neuberg-Str. 1
Hanover, Germany

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy